C. A. M. Fulgenzi Et Al. , "Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?," EXPERT OPINION ON INVESTIGATIONAL DRUGS , vol.31, pp.681-691, 2022
Fulgenzi, C. A. M. Et Al. 2022. Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?. EXPERT OPINION ON INVESTIGATIONAL DRUGS , vol.31 , 681-691.
Fulgenzi, C. A. M., D'Alessio, A., Ogunbiyi, O., DEMİRTAŞ, C. Ö., Gennari, A., Cortellini, A., ... Sharma, R.(2022). Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?. EXPERT OPINION ON INVESTIGATIONAL DRUGS , vol.31, 681-691.
Fulgenzi, Claudia Et Al. "Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?," EXPERT OPINION ON INVESTIGATIONAL DRUGS , vol.31, 681-691, 2022
Fulgenzi, Claudia A. Et Al. "Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?." EXPERT OPINION ON INVESTIGATIONAL DRUGS , vol.31, pp.681-691, 2022
Fulgenzi, C. A. M. Et Al. (2022) . "Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?." EXPERT OPINION ON INVESTIGATIONAL DRUGS , vol.31, pp.681-691.
@article{article, author={Claudia Angela Maria Fulgenzi Et Al. }, title={Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?}, journal={EXPERT OPINION ON INVESTIGATIONAL DRUGS}, year=2022, pages={681-691} }